Opendata, web and dolomites

STOP-COPD SIGNED

PulseHaler™: A Novel Treatment Device for COPD.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 STOP-COPD project word cloud

Explore the words cloud of the STOP-COPD project. It provides you a very rough idea of what is the project "STOP-COPD" about.

additional    kols    data    predictor    intend    clinical    incorporating    functions    exercise    finalize    seasoned    chronic    obstructive    opening    obtain    pulsehaler    launch    continue    demonstrated    actions    business    ltd    strategy    functional    substantially    copd    reimbursement    sufferers    patients    disease    patient    strongest    50m    seal    excellence    finalized    respinova    markets    gather    regulatory    treat    160    winning    annually    israel    small    trial    prepare    thereby    decades    initial    treatment    airways    annual    revolutionary    brea    shown    mortality    europeans    employees    magnitude    grant    usability    receiving    team    sites    device    efficacy    market    21b    kills    successful    burden    lungs    pulmonary    invented    reduce    commercial    life    trade    combined    arrangements    approval    first    capacity    smei    manufacturing    progressive    medical    debilitating    leadership    141b    collapse    quality    certificate    complete    morbidity    sme    difficult   

Project "STOP-COPD" data sheet

The following table provides information about the project.

Coordinator
RESPINOVA LTD 

Organization address
address: 8 HACHOSHLIM ST.
city: HERZLIYA PITUACH
postcode: 4672408
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://www.respinova.com
 Total cost 3˙449˙093 €
 EC max contribution 2˙414˙365 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2020-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESPINOVA LTD IL (HERZLIYA PITUACH) coordinator 2˙414˙365.00

Map

 Project objective

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, debilitating, disease of the lungs which affects 50M Europeans and kills 160,000 every year, with an annual cost burden of €141B. Respinova Ltd. has invented a novel device, called PulseHaler™, to treat COPD in a revolutionary way by opening the small airways, which are known to collapse in COPD patients thereby making it increasingly difficult to breathe. No other COPD treatment in the market today can effectively open the small airways. In a clinical trial, the PulseHaler™ was shown to substantially improve the functional capabilities and quality of life of COPD sufferers. If PulseHaler™ can reduce costs by the same magnitude to which it has been demonstrated to improve patient’s exercise capacity (the strongest predictor of morbidity and mortality), the current cost burden of COPD in Europe could be reduced by up to €21B annually.

After winning a SMEi-1 grant and receiving a Seal of Excellence certificate for our first SMEi-2 application, we intend to complete several actions which will bring the PulseHaler™ to the commercial market in this SMEi-2 project. The design of the device will be finalized incorporating features and functions identified in our successful SMEi-1 project. We will then prepare the PulseHaler™ for large scale manufacturing. We will test the PulseHaler™ in a clinical study of COPD patients across several sites, to gather additional efficacy and usability data identified by KOLs in SMEi-1 as important to support uptake of the product in the market. We will continue to develop our reimbursement strategy for initial markets, finalize distribution arrangements in those markets, obtain regulatory approval, and proceed to launch the PulseHaler™.

Respinova Ltd. is a 10 year old SME based in Israel with 7 employees. We have a seasoned management team with decades of combined medical device, business and leadership experience.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOP-COPD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOP-COPD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

Presque (2019)

Smart Nursing Bra

Read More  

Cancersensing (2019)

A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Read More